By Jennifer Schranz, MD, Global Head of Rare Diseases, Ipsen
The Current Rare Disease Landscape
Globally, there are roughly 400 million people living with one or more of the approximately 7,000 known rare diseases1. Within the diverse rare disease community, there are many stories that paint the broader picture of what it means to live with a rare disease. Every individual’s journey, from diagnosis to treatment, must be approached with respect and appreciation of the patient’s reality of living with a rare or ultra-rare disease.
As a member of the life sciences community, Ipsen is dedicated to working towards a better and healthier future for patients. That said, the reality of working with rare diseases is that there is often no textbook explanation for the natural history or development plan for a rare condition. Researchers may wander into the unknown, trying to uncover the pathophysiology of the rare condition to inform the pathway to effective and safe treatment – which requires flexibility and resiliency.
Firsthand Experience
Before I joined the Rare Disease team at Ipsen, my background was in infectious diseases. After graduating from medical school, I worked hands-on with people living with HIV/AIDS, which at the time, was severely underfunded, misunderstood, and stigmatized. The experience of working with patients who were dealing with a devastating disease fueled my desire to continue to research diseases that needed champions in the medical space.
Despite the hurdles that researchers may face when working to identify treatment options, I’ve found the light that continues to guide the way through the most challenging of cases is the patient and their caregivers. I have worked with patients, who despite being born with a rare condition, make it an opportunity to make a difference for their community.
Uniting the Patient Voice
I recall speaking with a mother of a wheelchair-bound boy with an ultra-rare, debilitating disorder who could only minimally communicate and required tube feedings for nutrition. Rather than viewing this as a challenge that would dictate their lives, his mother decided to take a proactive approach to supporting her child and others like him.
As a research-scientist, she used her skills to become the president of a patient organization and applied for research grants to understand the etiology of the condition and ultimately help find a cure. She spoke passionately about the progress researchers had made in the space – a result of her single-minded pursuit of a better life for her son and for those impacted by similar conditions.
Identifying a Path Forward
At Ipsen, our research decisions are guided by patient outcomes. Rare disease is a key therapeutic area for our R&D pipeline, and we work to involve patients every step of the way – from clinical trial design to patient advocacy relations. We pursue clinical programs that are first in class or best in class. We recently were able to share the results of our Natural History Study (NHS) of fibrodysplasia ossificans progressiva (FOP), a patient-focused study that is the first global, multi-center, longitudinal study designed to measure disease progression over three years2.
Personally, I feel it’s important to recognize that if you’re first, you’re often paving the road for future research. We understand that the journey to finding a treatment option for rare disease may be long and marked with many unanticipated detours and setbacks. At Ipsen, we pride ourselves on working directly with patients, physicians, nurses, patient association groups, and other stakeholders to understand the complexity of living with rare disease.
I am proud of what Ipsen has accomplished in the rare disease space. However, there is still work to do to better understand the full scope of research and resources needed to find treatment options for rare and ultra-rare diseases. Ipsen is committed and eager to work with the broader rare disease community to continue to fight for patients. Patients are the key to those seemingly impossible questions we try to answer when understanding rare diseases and are at the very center of everything we do.
To learn more about Ipsen and its ongoing commitment to the rare disease community, visit: https://www.ipsen.com/our-science/raredisease/.
©2022 Ipsen Biopharmaceuticals, Inc. All rights reserved.
February 2022, NON-US-002964
1Rare facts. Global Genes. (2020, December 16). Retrieved September 9, 2021, from https://globalgenes.org/rare-facts/.
2Al Mukaddam M et al. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. Journal of the Endocrine Society. 2020; DOI: https://doi.org/10.1210/jendso/bvaa046.254